KalVista Pharmaceuticals Files 10-Q for July 31, 2024

TL;DR

**KalVista Pharmaceuticals (KALV) filed its Q2 10-Q. Check financials.**

AI Summary

KalVista Pharmaceuticals, Inc. filed its 10-Q for the period ending July 31, 2024. The company, formerly known as Carbylan Therapeutics, Inc., reported its financial status and business operations. Key financial data and disclosures relevant to investors are included in this filing.

Why It Matters

This filing provides investors with an update on KalVista's financial health and operational progress for the quarter, crucial for understanding the company's trajectory in the pharmaceutical sector.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, KalVista faces inherent risks related to drug development, regulatory approvals, and market competition.

Key Numbers

• 0430 — Fiscal Year End (Indicates the end of the company's fiscal year.)
• 001-36830 — SEC File Number (Unique identifier for the company's SEC filings.)

Key Players & Entities

• KalVista Pharmaceuticals, Inc. (company) — Filer of the 10-Q
• Carbylan Therapeutics, Inc. (company) — Former name of KalVista Pharmaceuticals
• 20240731 (date) — End of reporting period
• 20240905 (date) — Filing date

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value per share KALV The Nasdaq

Filing Documents

• kalv-20240731.htm (10-Q) — 907KB
• kalv-ex10_1.htm (EX-10.1) — 494KB
• kalv-ex10_2.htm (EX-10.2) — 163KB
• kalv-ex31_1.htm (EX-31.1) — 17KB
• kalv-ex32_1.htm (EX-32.1) — 8KB
• 0000950170-24-103981.txt ( ) — 4731KB
• kalv-20240731.xsd (EX-101.SCH) — 570KB
• kalv-20240731_htm.xml (XML) — 604KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION Item 1.

Financial Statements (unaudited)

Financial Statements (unaudited) 3 Condensed Consolidated Balance Sheets 3 Condensed Consolidated Statements of Operations and Comprehensive Loss 4 Condensed Consolidated Statements of Changes in Stockholders' Equity 5 Condensed Consolidated Statements of Cash Flows 6 Notes to the Condensed Consolidated Financial Statements 7 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 13 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 19 Item 4.

Controls and Procedures

Controls and Procedures 19

OTHER INFORMATION

PART II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 20 Item 1A.

Risk Factors

Risk Factors 20 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 20 Item 3. Defaults Upon Senior Securities 20 Item 4. Mine Safety Disclosures 20 Item 5. Other Information 20 Item 6. Exhibits 21

FINANCI AL INFORMATION

PART I. FINANCI AL INFORMATION

FINANCI AL STATEMENTS

Item 1. FINANCI AL STATEMENTS KalVista Pharmaceuticals, Inc. Condensed Consolidated Ba lance Sheets (in thousands, except share and per share amounts) (Unaudited) July 31, April 30, 2024 2024 Assets Current assets: Cash and cash equivalents $ 31,848 $ 31,789 Marketable securities 142,424 178,612 Research and development tax credit receivable 9,908 8,439 Prepaid expenses and other current assets 7,454 6,850 Total current assets 191,634 225,690 Property and equipment, net 2,100 2,227 Right of use assets 5,859 6,920 Other assets 605 567 Total assets $ 200,198 $ 235,404 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 10,792 $ 9,107 Accrued expenses 10,355 12,398 Lease liability - current portion 1,264 1,302 Total current liabilities 22,411 22,807 Long-term liabilities: Lease liability - net of current portion 4,988 6,015 Total long-term liabilities 4,988 6,015 Commitments and contingencies (Note 6) Stockholders' equity Common stock, $ 0.001 par value, 100,000,000 authorized Shares issued and outstanding: 43,081,922 at July 31, 2024 and 42,521,975 at April 30, 2024 43 42 Additional paid-in capital 685,794 679,754 Accumulated deficit ( 510,169 ) ( 469,726 ) Accumulated other comprehensive loss ( 2,869 ) ( 3,488 ) Total stockholders' equity 172,799 206,582 Total liabilities and stockholders' equity $ 200,198 $ 235,404 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 3 KalVista Pharmaceuticals, Inc. Condensed Consolidated Statements of Opera tions and Comprehensive Loss (in thousands, except share and per share amounts) (Unaudited) Three Months Ended July 31, 2024 2023 Revenue $ — $ — Operating expenses: Research and development 26,614 19,307 General and administrative

View Full Filing

View this 10-Q filing on SEC EDGAR